18FFludarabine-PET in a murine model of multiple myelomaReport as inadecuate

18FFludarabine-PET in a murine model of multiple myeloma - Download this document for free, or read online. Document in PDF available to download.


Multiple myeloma MM is a haematological malignancy that affects plasma cells in the bone marrow. Recently, 18Ffludarabine has been introduced as an innovative PET radiotracer for imaging lymphoma. It demonstrated a great potential for accurate imaging of lymphoproliferative disorders. With the goal to question the usefulness of 18Ffludarabine-PET in other haematological diseases, an in vivo MM model was investigated.


RPMI8226-GFP-Luc MM cells expressing the green fluorescent protein GFP as well as the luciferase reporter Luc were derived from the parental RPMI8226 cells. They were injected subcutaneously into the flank of nude mice. Myeloma tumour growth was followed using bioluminescence-based imaging BLI and characterised by immunohistochemistry IHC. The tumour specificity of 18Ffludarabine was evaluated and compared to 18FFDG.


The tumoural uptake of 18FFDG was greater than that of 18Ffludarabine. However, the quantitative data extracted from IHC stainings were in better agreement with 18Ffludarabine, when compared to 18FFDG. The relationship between the tumoural uptake of 18F-labelled tracers and the BLI quantitative data was also in favour of 18Ffludarabine.


Our results suggest that 18Ffludarabine-PET might represent an alternative and perhaps more specific modality for MM imaging when compared to 18FFDG. Nevertheless, more investigations are required to extend this conclusion to humans.

Author: Narinée Hovhannisyan , Martine Dhilly, Martin Fidalgo, Fabien Fillesoye, Stéphane Guillouet, Brigitte Sola, Louisa Barré

Source: http://plos.srce.hr/


Related documents